Patents by Inventor Benjamin Wolozin

Benjamin Wolozin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NUCLEIC ACID BASED TIA-1 INHIBITORS
    Publication number: 20190142860
    Abstract: The disclosure provides, e.g., nucleic acid based inhibitors of TIA-1. The inhibitors can be, e.g., a double stranded RNA (e.g., a siRNA or shRNA), an antisense RNA, or a microRNA (miRNA). The nucleic acid based inhibitors can be used to treat, e.g., neurodegenerative disorders such as Alzheimer's disease and frontotemporal dementia.
    Type: Application
    Filed: October 14, 2016
    Publication date: May 16, 2019
    Inventors: Glenn R. Larsen, Benjamin Wolozin, Tara Vanderweyde, Daniel J. Apicco
  • IDENTIFICATION OF COMPOUNDS THAT DISPERSE TDP-43 INCLUSIONS
    Publication number: 20170088515
    Abstract: Herein, compounds and compositions for use in treating diseases relating to inclusion formation and stress granules are described. Methods for screening for modulation of TDP-43 aggregation are also described.
    Type: Application
    Filed: May 2, 2016
    Publication date: March 30, 2017
    Inventors: Benjamin Wolozin, Marcie Glicksman, Gregory D. Cuny, Justin Boyd
  • Identification of compounds that disperse TDP-43 inclusions
    Patent number: 9359363
    Abstract: Herein, methods of modulating inclusion formation and stress granules in cells are described. The methods comprise contacting a cell with an inclusion inhibitor. Methods for screening for modulators of TDP-43 aggregation are also described.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: June 7, 2016
    Assignees: AQUINNAH PHARMACEUTICALS, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Benjamin Wolozin, Marcie Glicksman, Gregory D. Cuny, Justin Boyd
  • identification of compounds that disperse tdp-43 inclusions
    Publication number: 20140080780
    Abstract: Herein, methods of modulating inclusion formation and stress granules in cells are described. The methods comprise contacting a cell with an inclusion inhibitor. Methods for screening for modulators of TDP-43 aggregation are also described.
    Type: Application
    Filed: May 21, 2012
    Publication date: March 20, 2014
    Inventor: Benjamin WOLOZIN
  • Isolated peptides to treat alpha-synuclein diseases
    Patent number: 7605133
    Abstract: The present invention relates to drug screening methods and methods of preventing neural tissue damage caused by ?-synuclein aggregation. These methods are especially useful in the design and development of inhibitors of Lewy body diseases and other synucleinopathies, and further useful in the treatment of such neurodegenerative diseases, particularly Parkinson's Disease.
    Type: Grant
    Filed: July 30, 2004
    Date of Patent: October 20, 2009
    Assignee: Panacea Pharmaceuticals, Inc.
    Inventors: Benjamin Wolozin, Natalie Ostretova-Golts, Michael S. Lebowitz
  • Sterilization of marine organisms by manipulation of DNA content
    Publication number: 20050149997
    Abstract: A novel method of generating a sterile marine organism is disclosed. The method of generating sterile wild type and transgenic marine organisms having triploid genomes is also disclosed. Specifically, we disclose methods of inducing sterility in a number of fish and other species such that their progeny cannot produce offspring by breeding organisms with tetraploid genomes to organisms with diploid genomes to produce triploid offspring.
    Type: Application
    Filed: November 4, 2004
    Publication date: July 7, 2005
    Inventors: Benjamin Wolozin, James Sellers
  • Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
    Publication number: 20050032131
    Abstract: The present invention relates to drug screening methods and methods of preventing neural tissue damage caused by ?-synuclein aggregation. These methods are especially useful in the design and development of inhibitors of Lewy body diseases and other synucleinopathies, and further useful in the treatment of such neurodegenerative diseases, particularly Parkinson's Disease.
    Type: Application
    Filed: July 30, 2004
    Publication date: February 10, 2005
    Inventors: Benjamin Wolozin, Natalie Ostretova-Golts, Michael Lebowitz
  • Compositions for inhibiting the aggregation pathway of &agr;-synuclein
    Patent number: 6780971
    Abstract: The present invention provides methods of determining aggregation of &agr;-synuclein, which are a hallmark of Lewy body diseases such as Parkinson's disease. Also disclosed are inhibitors of the aggregation, including magnesium and &agr;-synuclein binding peptides. The inhibitors are useful in the treatment of Lewy body diseases.
    Type: Grant
    Filed: July 9, 2001
    Date of Patent: August 24, 2004
    Assignee: Panacea Pharmaceuticals, Inc.
    Inventors: Benjamin Wolozin, Natalie Ostretova-Golts, Michael S. Lebowitz
  • METHOD FOR EVALUATING THE ABILITY OF A COMPOUND TO INHIBIT NEUROTOXICITY
    Publication number: 20030037344
    Abstract: This invention provides a method for evaluating the ability of a compound to inhibit neurotoxicity which comprises (a) contacting a cell which expresses a receptor for advanced glycation end product protein and a mutant presenilin-2 protein in a cell culture and the compound; (b) determining the level of cell death in the cell culture; and (c) comparing the level of cell death determined in step (b) with the amount determined in the absence of the compound so as to evaluate the ability of the compound to inhibit neurotoxicity.
    Type: Application
    Filed: December 23, 1997
    Publication date: February 20, 2003
    Inventors: DAVID STERN, SHI DU YAN, BENJAMIN WOLOZIN
  • Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
    Patent number: 6472421
    Abstract: Described are methods for treating, preventing, or reducing the risk of the onset of Alzheimer's disease by administering a therapeutically effective amount of an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (“HMG CoA reductase inhibitor”) to a patient who is at risk for a coronary or cerebrovascular event or at risk for Alzheimer's disease.
    Type: Grant
    Filed: November 13, 1998
    Date of Patent: October 29, 2002
    Assignee: Nymox Corporation
    Inventor: Benjamin Wolozin
  • Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
    Publication number: 20020151464
    Abstract: The present invention provides methods of determining aggregation of &agr;-synuclein, which are a hallmark of Lewy body diseases such as Parkinson's disease. Also disclosed are inhibitors of the aggregation, including magnesium and &agr;-synuclein binding peptides. The inhibitors are useful in the treatment of Lewy body diseases.
    Type: Application
    Filed: July 9, 2001
    Publication date: October 17, 2002
    Inventors: Benjamin Wolozin, Natalie Ostretova-Golts, Michael S. Lebowitz
  • The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
    Patent number: 5811310
    Abstract: The invention relates to an antigen associated with Alzheimer's disease and to antibodies specific for said antigen. This invention further relates to methods for diagnosing Alzheimer's disease utilizing assays containing Alzheimer's associated antigen, antibodies specific for said antigen and samples from an individual suspected of having Alzheimer's disease.
    Type: Grant
    Filed: December 23, 1994
    Date of Patent: September 22, 1998
    Assignee: Albert Einstein College of Medicine of Yeshiva Univ.
    Inventors: Hossein A. Ghanbari, Peter Davies, Benjamin Wolozin